NGM · Biotechnology

Protagonist Therapeutics, Inc. (PTGX) Stock

$143.73 +2.73% NGM: PTGX Healthcare

Valuation

MetricValue
Price$143.73
Market Cap$9.24B
P/E Ratio115.66
P/B Ratio11.04
P/S Ratio32.13
EPS (TTM)$-1.81
52-Week High$160.81
52-Week Low$62.24
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE12.03%
ROA9.36%
ROCE6.88%
Gross Margin100.00%
Operating Margin-6.47%
Net Margin29.40%
Debt/Equity0.01
Current Ratio17.76

Annual Financials (USD)

Metric20212022202320242025
Revenue$27.0M$27.0M$60.0M$434.0M$46.0M
Operating Profit$-126.0M$-131.0M$-94.0M$253.0M$-158.0M
Net Profit$-126.0M$-127.0M$-79.0M$275.0M$-130.0M
EPS$-2.65$-2.52$-1.39$4.23$-2.05
Op Margin-460.0%-494.2%-156.1%58.2%-343.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$348.0M$248.0M$358.0M$745.0M$670.0M
Total Liabilities$48.0M$32.0M$21.0M$69.0M$55.0M
Cash$124.0M$126.0M$187.0M$97.0M$128.0M
Borrowings$6.0M$4.0M$1.0M$11.0M$10.0M

Latest News

Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review Simply Wall St. · Jul 9, 2026 Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued Simply Wall St. · Jul 9, 2026 New Strong Buy Stocks for July 9th Zacks · Jul 9, 2026 Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed? Simply Wall St. · Jul 8, 2026 Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains? Zacks · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-108.0M$-108.0M$-70.0M$184.0M$58.0M
Investing Cash Flow$-17.0M$91.0M$-40.0M$-301.0M$-51.0M
Financing Cash Flow$6.0M$4.0M$38.0M$-1.0M$0
Net Cash Flow$6.0M$2.0M$61.0M$-89.0M$31.0M
Free Cash Flow$-109.0M$-109.0M$-71.0M$183.0M$56.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.14
EV / EBITDA101.19
FCF Yield1.46%
Quick Ratio21.71
Interest Coverage0.00
Return 1Y116.92%
Return 3Y765.95%
Return 5Y695.54%

Ownership

Insiders Held0.71%
Institutions Held125.34%
Institutions Float Held126.24%
Institutional HolderSharesReport Date
Blackrock Inc.9,779,3692026-03-31
Farallon Capital Management LLC6,348,9062026-03-31
UBS Group AG5,177,7962026-03-31
RTW Investments LP5,059,0532026-03-31
Wellington Management Group, LLP3,599,6442026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRSAclaris Therapeutics, Inc. $3.88 +2.25% -8.88 $541.24M 0.00%
ANABAnaptysBio, Inc. $46.03 -0.38% 7.19 $1.36B 0.00%
IMUXImmunic, Inc. $8.19 +8.33% -1.59 $111.56M 0.00%
IMVTImmunovant, Inc. $30.47 +0.69% -11.98 $6.29B 0.00%
IRONDisc Medicine, Inc. $62.16 +2.29% -9.92 $2.39B 0.00%

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is led by CEO Dinesh V. Patel, employs 132 people, headquartered in Newark, US, publicly traded since 2016.

Protagonist Therapeutics, Inc. (PTGX) stock trades at $143.73 with a market capitalization of $9.24B. The stock is valued at a price-to-earnings (P/E) ratio of 115.66, price-to-book of 11.04, price-to-sales of 32.13. Over the past 52 weeks the stock has ranged between $62.24 and $160.81, and currently trades 10.6% below its 52-week high.

On profitability, Protagonist Therapeutics, Inc. generates a return on equity (ROE) of 12.03%, above the typical market average, return on capital employed of 6.88%, an operating margin of -6.47%, a net profit margin of 29.40%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides